Millipore Sigma Vibrant Logo

IM37 Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4)

View Products on Sigmaaldrich.com
IM37
Ver preços e disponibilidade

Panorama geral

Replacement Information

Tabela com principais espec.

Species ReactivityHostAntibody Type
Gp, H, Rb, RMMonoclonal Antibody

Preço e Disponibilidade

Número de catálogo DisponibilidadeEmbalagem Qtde/Emb. Preço Quantidade
IM37-100UG
Verificando a disponibilidade...
Disponibilidade limitada
Disponibilidade limitada
Insira quantidade 
Descontinuado
Quantidades limitadas disponíveis
Disponibilidade a ser confirmada
    Restante: será informado
      Restante: será informado
      Vai informar
      Contatar o serviço de atendimento ao cliente
      Contact Customer Service

      Ampola plástica 100 μg
      Recuperando preço...
      O preço não pôde ser recuperado
      Quantidade mínima necessária para ser múltipla de
      Maximum Quantity is
      Após finalização do pedido Mais informações
      Você salvou ()
       
      Solicitar preço
      Description
      OverviewRecognizes the ~92 kDa latent and the ~83 kDa active forms of MMP-9 in breast carcinoma tissue.
      Catalogue NumberIM37
      Brand Family Calbiochem®
      SynonymsAnti-Gelatinase B, Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9
      Application Data
      Detection of human MMP-9 by immunoblotting. Sample: Conditioned medium of human fibrosarcoma HT1080 cells. Primary antibody: Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) (Cat. No. IM37) (2 µg/ml). Detection: chemiluminescence.
      References
      ReferencesCottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Okada, Y., et al., 1992. J. Biol. Chem. 267, 21712.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Product Information
      DeclarationManufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.
      FormLiquid
      FormulationIn 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0
      Negative controlMMP-2 protein (Cat. Nos. PF023 or PF037)
      Positive controlMMP-9 protein (Cat. Nos. PF024 or PF038) or breast carcinoma tissue
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoblotting, Original Clone Okada, Y., et al. 1992. J. Biol. Chem. 267, 21712. Immunohistochemistry Nakagawa, T., et al. 1994. J. Neurosurg. 81, 69. Tsuchiya, Y., et al. 1994. Int. J. Cancer 56, 46.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesFrozen Sections (see application references)
      Immunoblotting (1 µg/ml)
      Paraffin Sections (see application references)
      Application CommentsThis antibody does not react with MMP-1, MMP-2, MMP-3 or MMP-13. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena synthetic peptide corresponding to amino acids 626-644 of human MMP-9
      ImmunogenHuman
      Clone56-2A4
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Guinea Pig
      • Human
      • Rabbit
      • Rat
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de catálogo GTIN
      IM37-100UG 07790788053796

      Documentation

      Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) MSDS

      Título

      Ficha de Segurança de Produtos (MSDS) 

      Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) Certificados de análise

      TítuloNúmero do lote
      IM37

      Referências

      Visão geral de referência
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Okada, Y., et al., 1992. J. Biol. Chem. 267, 21712.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Ficha de dados

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision22-February-2011 RFH
      SynonymsAnti-Gelatinase B, Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9
      ApplicationFrozen Sections (see application references)
      Immunoblotting (1 µg/ml)
      Paraffin Sections (see application references)
      Application Data
      Detection of human MMP-9 by immunoblotting. Sample: Conditioned medium of human fibrosarcoma HT1080 cells. Primary antibody: Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) (Cat. No. IM37) (2 µg/ml). Detection: chemiluminescence.
      DescriptionPurified mouse monoclonal antibody (see application references). Recognizes both the ~92 kDa latent and the ~83 kDa active forms of MMP-9.
      BackgroundMatrix metalloproteinases (MMP's) are a family of enzymes that are responsible for the degradation of extracellular matrix components such as collagen, laminin and proteoglycans. In addition to sequence homology, all MMP's share the following characteristics: the catalytic mechanism is dependent upon a zinc ion at the active center, they cleave one or more extracellular matrix components, they are secreted as zymogens which are activated by removal of an ~10 kDa segment from the N-terminus and they are inhibited by tissue inhibitor of metalloproteinases (TIMP). These enzymes are involved in normal physiological processes such as embryogenesis and tissue remodeling and may play an important role in arthritis, periodontitis, and metastasis. MMP-9 (Gelatinase B, 92 kDa gelatinase/type IV collagenase) is secreted as a 92 kDa zymogen which is proteolytically processed to the 83 kDa active form. MMP-9 shows substrate specificity toward type IV and V collagens, gelatin and elastin.
      HostMouse
      Immunogen speciesHuman
      Immunogena synthetic peptide corresponding to amino acids 626-644 of human MMP-9
      Clone56-2A4
      IsotypeIgG₁
      Speciesnot bovine, guinea pig, not hamster, human, not mouse, rabbit, rat
      Positive controlMMP-9 protein (Cat. Nos. PF024 or PF038) or breast carcinoma tissue
      Negative controlMMP-2 protein (Cat. Nos. PF023 or PF037)
      FormLiquid
      FormulationIn 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsThis antibody does not react with MMP-1, MMP-2, MMP-3 or MMP-13. Antibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Standard Handling
      ReferencesCottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Okada, Y., et al., 1992. J. Biol. Chem. 267, 21712.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Application referencesImmunoblotting, Original Clone Okada, Y., et al. 1992. J. Biol. Chem. 267, 21712. Immunohistochemistry Nakagawa, T., et al. 1994. J. Neurosurg. 81, 69. Tsuchiya, Y., et al. 1994. Int. J. Cancer 56, 46.